Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic umbilical cord-derived mesenchymal stem cells (Hospital Infantil Universitario Niño Jesús)
- Development stage
- Unknown
- Lead developer
- Hospital Universitario Niño Jesús
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
This is an investigational cell therapy consisting of allogeneic mesenchymal stem cells (MSCs) derived from umbilical cord tissue (Wharton's jelly). Developed by the Hospital Infantil Universitario Niño Jesús in Madrid, Spain, it is being evaluated for the treatment of severe COVID-19 pneumonia and associated acute respiratory distress syndrome (ARDS). The therapy leverages the immunomodulatory and anti-inflammatory properties of MSCs to attenuate the uncontrolled cytokine cascade and inflammatory response in the lungs, potentially promoting tissue repair and improving respiratory function. The cells are administered via intravenous infusion and are currently being tested in a Phase II clinical trial (NCT04366271).
- Other names
- Allogeneic mesenchymal cells from umbilical cord tissueUC-MSCsWharton's jelly-derived mesenchymal stem cellsmesenchymal cells-Hospital Infantil Universitario Niño Jesús, Madrid, Spain-COVID-19 pneumonia
Beyond the preview
Go deeper on allogeneic umbilical cord-derived mesenchymal stem cells (Hospital Infantil Universitario Niño Jesús).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic umbilical cord-derived mesenchymal stem cells (Hospital Infantil Universitario Niño Jesús).